IMAGE: Provided
Anand was awarded LB2C funding for his project titled “Targeting Virus Breathing Hotspots for Antibody Discovery.” Anand looks for vulnerabilities on a virus that could be tapped to generate antibodies for use in antiviral therapies. He is particularly interested in understanding the structural changes of viral surface proteins as the virus dissembles and enters human host cells. These structural changes part of a process called viral breathing could reveal critical locations called epitopes where antibodies can bind to the virus.
Anand will then work with collaborators to test the effectiveness of antibodies designed to target certain epitopes that, for example, occur across a variety of virus variants or are particularly accessible. This approach, which uniquely seeks to merge the biophysical insights of viral breathing with targeted antibody discovery, preemptively identifies new antibodies and could thus greatly advance viral pandemic preparedness.
Are antibody cocktails the key to COVID-19 treatment?
Thought LeadersDr. Natalia FreundAssistant Professor, Sackler School of MedicineTel Aviv University
In this interview, News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.
What provoked your research into the ongoing COVID-19 pandemic?
When the pandemic hit Israel, every aspect of our lives has changed, and therefore like many other laboratories we had to put on hold some ongoing projects and focus on the new virus.
In fact, we have been developing tools and platforms for antibody discovery and isolation for a very long time, while focusing on other infectious diseases such as HIV-1 and Tuberculosis, and we were as prepared as one can be to apply our tools to the new COVID-19 problem.
OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
OSE and MAbSilico joined their efforts to demonstrate the power of a fully computational
in silico Antibody Discovery and Design platform. The expanded collaboration agreement will now be applied to 10 antibody programs.
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005756/en/
OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) today announced a new collaboration agreement with MAbSilico, a deep technology innovative TechBio located in Tours, France, to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development.
OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins
Jan 12 2021
OXGENE™, a biotechnology company offering integrated discovery and manufacturing technologies to the cell and gene therapy industry, announces the introduction of its self-labelling integral membrane (SLIM™) protein discovery system.
The novel method allows for the identification of antibodies against membrane proteins in their native configuration in mammalian cells, which could catalyse the discovery of new candidates for antibody-based therapies.
In SLIM display, a target membrane protein and a library of potential binders are expressed in the same mammalian cells. These then progress through multiple rounds of enrichment and purification to obtain a single clone expressing a single-chain variable fragment that can bind the target antigen.